IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe

Advances in Therapy

Volumn 32, Issue 2, 2015, Pages 87-107

  Duck, Annette ^a   Pigram, Lucy ^b   Errhalt, Peter ^c   Ahmed, Deeba ^d   Chaudhuri, Nazia ^e  

^a Independent Interstitial Lung Disease Specialist Nurse   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c University Hospital Krems   (Austria)

^d InterMune UK and Ireland   (United Kingdom)

^e MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Idiopathic pulmonary fibrosis; Patient education; Patient support; Pirfenidone; Respirology

Indexed keywords

PIRFENIDONE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

AUSTRIA; DOCTOR NURSE RELATION; EUROPE; FIBROSING ALVEOLITIS; HEALTH PROGRAM; HUMAN; INTERPERSONAL COMMUNICATION; PATIENT EDUCATION; PATIENT SATISFACTION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SUPPORT GROUP; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; ADULT; DISEASE MANAGEMENT; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; NURSE; ORGANIZATION AND MANAGEMENT; QUESTIONNAIRE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE MANAGEMENT; EUROPE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; NURSES; PATIENT EDUCATION AS TOPIC; PYRIDONES; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84925511841     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0183-7     Document Type: Review

References (35)

1. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636–43.
2. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006;3:285–92.
3. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40.
4. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008;3:8.
5. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
6. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61:980–5.
7. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax. 2002;57:338–42.
8. Karakatsani A, Papakosta D, Rapti A, et al. Epidemiology of interstitial lung diseases in Greece. Respir Med. 2009;103:1122–9.
9. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax. 2011;66:462–7.
10. Thomeer MJ, Costabe U, Rizzato G, Poletti V, Demedts M. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J Suppl. 2001;32:114s–8s.
11. von Plessen C, Grinde O, Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med. 2003;97:428–35.
12. Grattendick KJ, Nakashima JM, Feng L, Giri SN, Margolin SB. Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro. Int Immunopharmacol. 2008;8:679–87.
13. Liu H, Drew P, Gaugler AC, Cheng Y, Visner GA. Pirfenidone inhibits lung allograft fibrosis through l-arginine-arginase pathway. Am J Transplant. 2005;5:1256–63.
14. Nakayama S, Mukae H, Sakamoto N, et al. Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci. 2008;82:210–7.
15. Oku H, Nakazato H, Horikawa T, Tsuruta Y, Suzuki R. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol. 2002;446:167–76.
16. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590:400–8.
17. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011;20:85–97.
18. InterMune (2014) Products–about pirfenidone. http://www.intermune.com/products. Accessed Dec 2014.
19. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040–7.
20. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–92.
21. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–9.
22. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821–9.
23. Esbriet (pirfenidone) (2014) Summary of product characteristics: Esbriet 267 mg hard capsules. http://www.medicines.org.uk/EMC/medicine/26942/SPC/Esbriet+267+mg+hard+capsules/. Accessed Nov 2014.
24. Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014;19:740–7.
25. Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014;31:375–91.
26. Huang Y, Yap SR, Seiwert SD, Pan L. Nonclinical studies suggest simple strategies to further improve the GI tolerability of Pirfenidone. Am J Respir Crit Care Med. 2014;189(A38):A1420 ATS conference abstracts.
27. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health J Int Soc Pharma Outcomes Res. 2008;11:44–7.
28. Giot C, Maronati M, Becattelli I, Schoenheit G (2013) Idiopathic pulmonary fibrosis: an EU patient perspective survey. Curr Respir Med Rev 9:112–9(8).
29. Al-Abri R, Al-Balushi A. Patient satisfaction survey as a tool towards quality improvement. Oman Med J. 2014;29:3–7.
30. Anhang Price R, Elliott MN, Zaslavsky AM, et al. Examining the role of patient experience surveys in measuring health care quality. Med Care Res Rev. 2014;71(5):522–54.
31. Chaudhuri N, Duck A, Frank R, Holme J, Leonard C. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108:224–6.
32. MacQuarrie JL, Lebel F. Pirfenidone use in clinical practice: analysis of data from a Canadian patient support program for patients with idiopathic pulmonary fibrosis (INSPIRATION). Am J Respir Crit Care Med. 2014;189:A1428.
33. Chuang C, Levine SH, Rich J. Enhancing cost-effective care with a patient-centric chronic obstructive pulmonary disease program. Popul Health Manag. 2011;14:133–6.
34. Cramm JM, Nieboer AP. The relationship between self-management abilities, quality of chronic care delivery, and wellbeing among patients with chronic obstructive pulmonary disease in The Netherlands. Int J Chron Obstruct Pulmon Dis. 2013;8:209–14.
35. Dall TM, Askarinam Wagner RC, Zhang Y, W Yang, Arday DR, Gantt CJ. Outcomes and lessons learned from evaluating TRICARE’s disease management programs. Am J Manag Care. 2010;16:438–46.